XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.3

REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables)

9 Months Ended

Sep. 30, 2024

Concentration Risk And Geographic Information [Abstract]

Schedule of Disaggregation of Total Net Product Revenues by Product

The following table presents Total Revenues and disaggregates Net Product Revenues by product.

			Three Months Ended September 30,												Nine Months Ended September 30,
			2024						2023						2024						2023
VOXZOGO			$	189,785					$	122,973					$	526,597					$	324,146
VIMIZIM			178,158						158,869						548,694						525,453
NAGLAZYME			131,906						108,916						369,584						322,040
PALYNZIQ			90,634						78,885						254,634						216,105
ALDURAZYME			71,029						13,812						144,849						88,533
BRINEURA			37,005						41,042						121,361						118,244
KUVAN			28,115						42,947						92,576						144,047
ROCTAVIAN			7,235						822						15,516						822
Total net product revenues			733,867						568,266						2,073,811						1,739,390
Royalty and other revenues			11,873						13,063						32,791						33,629
Total revenues			$	745,740					$	581,329					$	2,106,602					$	1,773,019

Schedule of Disaggregation of Total Net Product Revenues by Geographic Region

The table below disaggregates total Net Product Revenues by geographic region, which is based on patient location for the Company's commercial products sold directly by the Company, except for ALDURAZYME, which is marketed and sold exclusively by Sanofi worldwide.

			Three Months Ended September 30,												Nine Months Ended September 30,
			2024						2023						2024						2023
United States			$	235,515					$	194,745					$	655,963					$	553,184
Europe			191,017						168,784						607,755						512,910
Latin America			111,908						81,524						274,920						224,716
Rest of world			124,398						109,401						390,324						360,047
Total net product revenues marketed by the Company			$	662,838					$	554,454					$	1,928,962					$	1,650,857
ALDURAZYME net product revenues marketed by Sanofi			71,029						13,812						144,849						88,533
Total net product revenues			$	733,867					$	568,266					$	2,073,811					$	1,739,390

Schedule of Total Net Product Revenue Concentrations Attributed to Largest Customers

The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented.

			Three Months Ended September 30,												Nine Months Ended September 30,
			2024						2023						2024						2023
Customer A			12		%				13		%				11		%				12		%
Customer B			11						15						13						15
Customer C			10						10						10						10
Total			33		%				38		%				34		%				37		%

X

- Definition

Concentration risk and geographic information.

+ References

No definition available.

+ Details

Name:	bmrn_ConcentrationRiskAndGeographicInformationAbstract
Namespace Prefix:	bmrn_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-21

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-20

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-18

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-20

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 16
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-16

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-21

+ Details

Name:	us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration